睿知中国医院研究地图
候选清单

正在招募乳腺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer

ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由江苏省肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方江苏省肿瘤医院Jiangsu Cancer Hospital南京医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07601178,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Prior treatment with any agent targeting the mechanism of tumor immunotherapy, including immune checkpoint inhibitors (e.g., anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-CTLA-4 antibodies), immune checkpoint agonists (e.g., antibodies targeting ICOS, CD40, CD137, GITR, OX40), or immune cell therapy.

    排除标准第 9 条

  3. ECOG performance status 0 or 1.

    入选标准第 8 条

  4. Platelet or red blood cell transfusion within 4 weeks before initiation of study drug treatment.

    排除标准第 23 条

  5. At least one measurable tumor lesion according to RECIST 1.1 criteria.

    入选标准第 6 条

  6. Known or self-reported human immunodeficiency virus (HIV) infection.

    排除标准第 7 条

    HBV-DNA positive or HCV-DNA positive (copy number >10³).

    排除标准第 8 条

    Presence of other malignancies within 5 years before enrollment, except for TNBC.

    排除标准第 13 条

  7. Female participants who are pregnant, breastfeeding, or planning to become pregnant during the study.

    排除标准第 25 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义)。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07601178,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Participants voluntarily join the study, sign the informed consent form, and agree to strictly comply with the study protocol requirements.
  2. Female patients aged between 18 and 75 years.
  3. Confirmed by histopathological examination as advanced triple-negative invasive breast cancer, meeting the following criteria: pathological type triple-negative, specifically: ER negative (IHC <1%), PR negative (IHC <1%), HER2 negative (IHC -/+ or IHC ++ but FISH/CISH negative). Priority is given to pathology from metastatic lesions; if metastatic lesion pathology is not available, primary lesion pathology may be used.
  4. TNBC patients with initial diagnosis of stage IV (according to AJCC 8th edition) or recurrent/metastatic disease who are not suitable for surgery, and have not received prior systemic therapy for advanced disease. Prior neoadjuvant and/or adjuvant therapy with taxanes or other anti-tumor treatments is permitted, provided that there was no disease progression during neoadjuvant therapy, and the interval between completion of taxane-based (neo)adjuvant therapy and recurrence/metastasis is ≥6 months.
  5. Suitable for nab-paclitaxel treatment.
  6. At least one measurable tumor lesion according to RECIST 1.1 criteria.
  7. Expected survival ≥3 months.
  8. ECOG performance status 0 or 1.
  9. Adequate organ function, including:

排除标准:Exclusion Criteria:

  1. Known history of severe allergic reactions to QL1706, anlotinib, nab-paclitaxel, or any of their excipients.
  2. Inability to swallow oral medications, or any gastrointestinal disorder that may interfere with the absorption and metabolism of the study drugs.
  3. Symptomatic brain/leptomeningeal metastases and/or spinal cord metastases.
  4. Active or potentially relapsing autoimmune disease, with the following exceptions: vitiligo, alopecia, psoriasis, or eczema not requiring systemic treatment; hypothyroidism due to autoimmune thyroiditis requiring only stable-dose hormone replacement therapy; type I diabetes mellitus requiring only stable-dose insulin replacement therapy.
  5. Major surgery within 3 weeks before study initiation, or failure to recover from surgery.
  6. History of organ transplantation or autologous/allogeneic stem cell transplantation.
  7. Known or self-reported human immunodeficiency virus (HIV) infection.
  8. HBV-DNA positive or HCV-DNA positive (copy number >10³).
  9. Prior treatment with any agent targeting the mechanism of tumor immunotherapy, including immune checkpoint inhibitors (e.g., anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-CTLA-4 antibodies), immune checkpoint agonists (e.g., antibodies targeting ICOS, CD40, CD137, GITR, OX40), or immune cell therapy.
  10. Prior treatment with anti-angiogenic targeted therapy.
  11. Hypertension that cannot be well controlled with a single antihypertensive medication (systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥90 mmHg).
  12. Arterial/venous thrombotic events (e.g., cerebrovascular accident including transient ischemic attack, deep vein thrombosis, pulmonary embolism) within 6 months before enrollment.
  13. Presence of other malignancies within 5 years before enrollment, except for TNBC.
  14. Tumor invasion or compression of surrounding major blood vessels or organs.
  15. Active central nervous system (CNS) metastatic lesions.
  16. Clinically significant pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
  17. History of myocarditis, cardiomyopathy, or malignant arrhythmias.
  18. History of significant bleeding tendency or coagulation dysfunction.
  19. History of esophageal-gastric varices, severe ulcer, non-healing wound, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding within 6 months before the first dose.
  20. Known active tuberculosis (TB).
  21. History of or current non-infectious pneumonitis/interstitial lung disease requiring systemic corticosteroid therapy.
  22. Major surgery or severe trauma within 30 days before the first dose, or planned major surgery within 30 days after the first dose; minor local surgery within 3 days before the first dose.
  23. Platelet or red blood cell transfusion within 4 weeks before initiation of study drug treatment.
  24. Receipt of live vaccine within 4 weeks before the first dose, or planned receipt of live vaccine during the study.
  25. Female participants who are pregnant, breastfeeding, or planning to become pregnant during the study.
  26. Patients judged by the investigator to be unsuitable for participation in this study.

引自 ClinicalTrials.gov, NCT07601178, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07601178,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07601178